Compare Constellation Energy Corporation (CEG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs BIO-TECHNE Corp — how do they compare? Constellation Energy Corporation trades at $277.66 (market cap $95.82B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: Constellation Energy Corporation is far larger — about 8.5× BIO-TECHNE Corp's market cap, and Constellation Energy Corporation pays the higher dividend (0.63%). Which is the better fit depends on your goals.
| CEG | TECH | |
|---|---|---|
Market Cap | $95.82B | $11.24B |
Sector | Energy | Health |
52-Week High | $403.95 | $72.29 |
52-Week Low | $236.50 | $43.31 |
Enterprise Value | $119.82B | $11.32B |
Dividend Yield | 0.63% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $269.89, up 3.37% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.55 versus $2.29 expected, and the company raised its 2026 guidance. Recent news highlights new power deals, including a Walmart PPA, and the acquisition of Calpine, positioning CEG to benefit from AI-driven electricity demand.
The outlook is positive with a consensus price target of $333.14, implying significant upside. Key opportunities include nuclear energy's role in the AI power boom and strong cash flow generation. Risks involve execution of growth initiatives and potential regulatory changes affecting the utilities sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
